NEWS
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
MaxCyte (Nasdaq: MXCT; LSE: MXCT) and Kamau Therapeutics have entered a strategic platform license agreement. Kamau gains non-exclusive rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform for research, clinical, and commercial purposes. In return, MaxCyte will receive annual licensing fees and program-related revenue.
Kamau, a clinical-stage company, is developing gene correction therapies using homology-directed repair (HDR) editing. Their lead program, nula-cel, targets sickle cell disease (SCD). This partnership aims to optimize Kamau's clinical manufacturing process and expedite the development of potential cures for genetic diseases.
MaxCyte's ExPERT™ platform offers high transfection efficiency, scalability, and enhanced functionality for complex cell engineering. This marks MaxCyte's 29th clinical/commercial partnership, contributing to its pre-commercial milestone revenue stream.
Kamau, a clinical-stage company, is developing gene correction therapies using homology-directed repair (HDR) editing. Their lead program, nula-cel, targets sickle cell disease (SCD). This partnership aims to optimize Kamau's clinical manufacturing process and expedite the development of potential cures for genetic diseases.
MaxCyte's ExPERT™ platform offers high transfection efficiency, scalability, and enhanced functionality for complex cell engineering. This marks MaxCyte's 29th clinical/commercial partnership, contributing to its pre-commercial milestone revenue stream.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1991Followers
101Following
17KVisitors
Follow